Nimbus Therapeutics

Nimbus Therapeutics is a biotechnology company based in Cambridge, Massachusetts, specializing in the discovery and development of medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company employs a computational technology-driven approach to advance a diverse pipeline of novel small molecule therapeutics. Within its portfolio, the Nimbus Apollo program focuses on the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase, aimed at treating non-alcoholic steatohepatitis and potentially hepatocellular carcinoma. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration, highlighting its significance in addressing unmet medical needs. Nimbus Therapeutics has established strategic partnerships to enhance its research and development capabilities.